CARTER-WALLACE FELBATOL DISCONTINUED USE RECOMMENDED DUE TO APLASTIC ANEMIA; FELBAMATE LOSS COULD MEAN THREE C-W Rx PRODUCTS OFF MARKET IN A YEAR

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".